Predictive immunomonitoring-The COST ENTIRE initiative

Clinical Immunology

Volumn 147, Issue 1, 2013, Pages 23-26

  Popadic, Dusan ^a   Anegon, Ignacio ^b   Baeten, Dominique ^c   Eibel, Hermann ^d   Giese, Thomas ^e   Marits, Per ^f   Martinez Caceres, Eva ^g   Mascart, Françoise ^h   Nestle, Frank ⁱ   Pujol Borrell, Ricardo ^j   Savic, Emina ^a   Scheibenbogen, Carmen ^k   Seliger, Barbara ^l   Thunberg, Sarah ^m   Turina, Maureen ^c   Villanova, Federica ⁱ   Winqvist, Ola ^f   Wikström, Ann Charlotte ^m  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b Centre National de la Recherche Scientifique   (France)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f KAROLINSKA INSTITUTE   (Sweden)

^g UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^h ERASME HOSPITAL   (Belgium)

ⁱ ST THOMAS HOSPITAL   (United Kingdom)

^j HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^k CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^l MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^m KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD ANALYSIS; EDITORIAL; EVIDENCE BASED MEDICINE; HEALTH CARE ORGANIZATION; HUMAN; IMMUNE MEDIATED INFLAMMATORY DISEASE; IMMUNOLOGICAL MONITORING; IMMUNOPATHOLOGY; IMMUNOPHENOTYPING; INFLAMMATION; LABORATORY TEST; MEDICAL LITERATURE; MEDICAL RESEARCH; PRIORITY JOURNAL;

EUROPE; HEALTH PROMOTION; HUMANS; IMMUNE SYSTEM DISEASES; INFLAMMATION; INTERNATIONAL COOPERATION; ORGANIZATIONAL OBJECTIVES; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84874533956     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.01.013     Document Type: Editorial

References (13)

1. El-Gabalawy H., Guenther L.C., Bernstein C.N. Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J. Rheumatol. Suppl. 2010, 85:2-10.
2. Bressler B., Haraoui B., Keystone E., Sette A. Optimizing use of tumor necrosis factor inhibitors in the management of immune-mediated inflammatory diseases. J. Rheumatol. Suppl. 2010, 85:40-52.
3. Gabay C., Lamacchia C., Palmer G. IL-1 pathways in inflammation and human diseases. Nat. Rev. Rheumatol. 2010, 6:232-241.
4. Murakami M., Nishimoto N. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective. Curr. Opin. Rheumatol. 2011, 23:273-277.
5. Kappos L., Bates D., Edan G., Eraksoy M., Garcia-Merino A., Grigoriadis N., Hartung H.P., Havrdova E., Hillert J., Hohlfeld R., Kremenchutzky M., Lyon-Caen O., Miller A., Pozzilli C., Ravnborg M., Saida T., Sindic C., Vass K., Clifford D.B., Hauser S., Major E.O., O'Connor P.W., Weiner H.L., Clanet M., Gold R., Hirsch H.H., Radu E.W., Sorensen P.S., King J. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 2011, 10:745-758.
6. Oliver B.J., Kohli E., Kasper L.H. Interferon therapy in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of the comparative trials. J. Neurol. Sci. 2011, 302:96-105.
7. Yazici Y. Rheumatoid arthritis: when should we use rituximab to treat RA?. Nat. Rev. Rheumatol. 2011, 7:379-380.
8. Singh J.A., Wells G.A., Christensen R., Tanjong Ghogomu E., Maxwell L., Macdonald J.K., Filippini G., Skoetz N., Francis D., Lopes L.C., Guyatt G.H., Schmitt J., La Mantia L., Weberschock T., Roos J.F., Siebert H., Hershan S., Lunn M.P., Tugwell P., Buchbinder R. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst. Rev. 2011, CD008794.
9. Clifford D.B., De Luca A., Simpson D.M., Arendt G., Giovannoni G., Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010, 9:438-446.
10. Major E.O. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu. Rev. Med. 2010, 61:35-47.
11. Schraven B., Kalinke U. CD28 superagonists: what makes the difference in humans?. Immunity 2008, 28:591-595.
12. Maecker H.T., McCoy J.P., Amos M., Elliott J., Gaigalas A., Wang L., Aranda R., Banchereau J., Boshoff C., Braun J., Korin Y., Reed E., Cho J., Hafler D., Davis M., Fathman C.G., Robinson W., Denny T., Weinhold K., Desai B., Diamond B., Gregersen P., Di Meglio P., Nestle F.O., Peakman M., Villanova F., Ferbas J., Field E., Kantor A., Kawabata T., Komocsar W., Lotze M., Nepom J., Ochs H., O'Lone R., Phippard D., Plevy S., Rich S., Roederer M., Rotrosen D., Yeh J.H. A model for harmonizing flow cytometry in clinical trials. Nat. Immunol. 2010, 11:975-978.
13. Maecker H.T., McCoy J.P., Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat. Rev. Immunol. 2012, 12:191-200.